CPI-1189

CPI-1189 is a benzamide with neuroprotective and anti-inflammatory activities. It inhibits phosphorylation of p38 MAPK in IL-1beta-stimulated primary rat astrocytes by 70 to 80% when used at concentrations ranging from 10 to 300 nM. CPI-1189 (20 mg/kg per day) reduces TNF-alpha-induced apoptosis in the corpus callosum and septum, but not in the neocortex or basal ganglia, as well as reduces TNF-alpha-induced decreases in GFAP levels in isolated rat brain slices. It decreases the latency to find the platform in the Morris water maze, indicating reversal of memory deficits, induced by TNF-alpha in a rat model of AIDS dementia when administered at a dose of 20 mg/kg per day. CPI-1189 (30 mg/kg per day) reduces crypt loss and decreases the number of ulcers and inflammatory cells in colonic lesions in mouse models of colitis induced by TNBS or dextran sulfate sodium (DSS, Cay-23250).Formal Name: 4-(acetylamino)-N-(1,1-dimethylethyl)-benzamide. CAS Number: 183619-38-7. Molecular Formula: C13H18N2O2. Formula Weight: 234.3. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 20mg/mL, DMSO: 20mg/mL, Ethanol: 20mg/mL, Ethanol:PBS (pH 7.2) (1:5): 0.16mg/mL. lambdamax: 265 nm. SMILES: CC(NC1=CC=C(C(NC(C)(C)C)=O)C=C1)=O. InChi Code: InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17). InChi Key: DJKNRCWSXSZACF-UHFFFAOYSA-N.